GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2007

Aptuit Purchases Evotec’s Chemical Development Business for $63.9M

  • Evotec sold its chemical development arm to Aptuit for £31.5 million, or about $63.9 million, in cash. This business comprises process research and development (PRD), custom preparation, analytical development, pilot plant manufacturing, and formulation.

    The chemical development segment reportedly generated €26.8 million through third-party revenues for the full-year 2006. This represents 40% of 2006 total group revenues.

    The transaction will allow Evotec to focus on its pharmaceutical division. “The excellent terms achieved in this transaction put us in a much stronger position to leverage our clinical CNS assets,” says Jorn Aldag, president and CEO.

    For Aptuit, the acquisition will add to its drug development service offerings. “We will integrate the highly regarded scientific staff and two pilot plants in Oxford and state-of-the-art parenteral fill/finish capabilities in Glasgow into our existing global network,” says Michael A. Griffith, CEO, and founder of Aptuit. “We will then leverage those capabilities to drive our commercial-scale capabilities in India.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »